426 related articles for article (PubMed ID: 19902320)
1. Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor.
Ihm SH; Chang K; Kim HY; Baek SH; Youn HJ; Seung KB; Kim JH
Basic Res Cardiol; 2010 May; 105(3):399-407. PubMed ID: 19902320
[TBL] [Abstract][Full Text] [Related]
2. Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or -gamma agonists in a type 2 diabetic animal model.
Kim SK; Zhao ZS; Lee YJ; Lee KE; Kang SM; Choi D; Lim SK; Chung N; Lee HC; Cha BS
Diabetes Metab Res Rev; 2003; 19(6):487-93. PubMed ID: 14648808
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
[TBL] [Abstract][Full Text] [Related]
4. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.
Choi KC; Ryu OH; Lee KW; Kim HY; Seo JA; Kim SG; Kim NH; Choi DS; Baik SH; Choi KM
Biochem Biophys Res Commun; 2005 Oct; 336(3):747-53. PubMed ID: 16157299
[TBL] [Abstract][Full Text] [Related]
5. Effect of rosiglitazone on the expression of cardiac adiponectin receptors and NADPH oxidase in type 2 diabetic rats.
Guo Z; Qin Z; Zhang R; Li J; Yin Y
Eur J Pharmacol; 2012 Jun; 685(1-3):116-25. PubMed ID: 22542658
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model.
Wang K; Zhou Z; Zhang M; Fan L; Forudi F; Zhou X; Qu W; Lincoff AM; Schmidt AM; Topol EJ; Penn MS
J Pharmacol Exp Ther; 2006 Apr; 317(1):37-43. PubMed ID: 16368901
[TBL] [Abstract][Full Text] [Related]
7. Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats.
Rose M; Balakumar P; Singh M
Pharmacology; 2007; 80(2-3):177-84. PubMed ID: 17570955
[TBL] [Abstract][Full Text] [Related]
8. Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice.
Nan YM; Fu N; Wu WJ; Liang BL; Wang RQ; Zhao SX; Zhao JM; Yu J
Scand J Gastroenterol; 2009; 44(3):358-65. PubMed ID: 18991162
[TBL] [Abstract][Full Text] [Related]
9. Targeting apoptosis in the heart of streptozotocin-induced diabetic rats.
Baraka A; AbdelGawad H
J Cardiovasc Pharmacol Ther; 2010 Jun; 15(2):175-81. PubMed ID: 20133494
[TBL] [Abstract][Full Text] [Related]
10. Effect of peroxisome proliferator-activated receptor gamma ligand. Rosiglitazone on left ventricular remodeling in rats with myocardial infarction.
Geng DF; Wu W; Jin DM; Wang JF; Wu YM
Int J Cardiol; 2006 Oct; 113(1):86-91. PubMed ID: 16891009
[TBL] [Abstract][Full Text] [Related]
11. Connective tissue growth factor induction in a pressure-overloaded heart ameliorated by the angiotensin II type 1 receptor blocker olmesartan.
Iwamoto M; Hirohata S; Ogawa H; Ohtsuki T; Shinohata R; Miyoshi T; Hatipoglu FO; Kusachi S; Yamamoto K; Ninomiya Y
Hypertens Res; 2010 Dec; 33(12):1305-11. PubMed ID: 20944640
[TBL] [Abstract][Full Text] [Related]
12. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates acrolein-induced airway mucus hypersecretion in rats.
Liu DS; Liu WJ; Chen L; Ou XM; Wang T; Feng YL; Zhang SF; Xu D; Chen YJ; Wen FQ
Toxicology; 2009 Jun; 260(1-3):112-9. PubMed ID: 19464576
[TBL] [Abstract][Full Text] [Related]
13. Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism.
Moulin D; Bianchi A; Boyault S; Sebillaud S; Koufany M; Francois M; Netter P; Jouzeau JY; Terlain B
Arthritis Rheum; 2005 Mar; 52(3):759-69. PubMed ID: 15751073
[TBL] [Abstract][Full Text] [Related]
14. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces the development of nonseptic shock induced by zymosan in mice.
Cuzzocrea S; Pisano B; Dugo L; Ianaro A; Patel NS; Di Paola R; Genovese T; Chatterjee PK; Fulia F; Cuzzocrea E; Di Rosa M; Caputi AP; Thiemermann C
Crit Care Med; 2004 Feb; 32(2):457-66. PubMed ID: 14758164
[TBL] [Abstract][Full Text] [Related]
15. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway.
Ogata T; Miyauchi T; Sakai S; Takanashi M; Irukayama-Tomobe Y; Yamaguchi I
J Am Coll Cardiol; 2004 Apr; 43(8):1481-8. PubMed ID: 15093887
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of proliferation and transforming growth factor beta3 protein expression by peroxisome proliferators-activated receptor gamma ligands in human uterine leiomyoma cells.
Zhang CH; Wen ZQ; Li JF; Li CZ; Shi M; Yang GW; Lan SM; Zhu Y; Wang F; Zhang YJ; Wang YY; Zhang H
Chin Med J (Engl); 2008 Jan; 121(2):166-71. PubMed ID: 18272045
[TBL] [Abstract][Full Text] [Related]
17. Pioglitazone reverses down-regulation of cardiac PPARgamma expression in Zucker diabetic fatty rats.
Pelzer T; Jazbutyte V; Arias-Loza PA; Segerer S; Lichtenwald M; Law MP; Schäfers M; Ertl G; Neyses L
Biochem Biophys Res Commun; 2005 Apr; 329(2):726-32. PubMed ID: 15737646
[TBL] [Abstract][Full Text] [Related]
18. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
Sorrentino SA; Bahlmann FH; Besler C; Müller M; Schulz S; Kirchhoff N; Doerries C; Horváth T; Limbourg A; Limbourg F; Fliser D; Haller H; Drexler H; Landmesser U
Circulation; 2007 Jul; 116(2):163-73. PubMed ID: 17592079
[TBL] [Abstract][Full Text] [Related]
19. Intra-coronary administration of soluble receptor for advanced glycation end-products attenuates cardiac remodeling with decreased myocardial transforming growth factor-beta1 expression and fibrosis in minipigs with ischemia-reperfusion injury.
Lu L; Zhang Q; Xu Y; Zhu ZB; Geng L; Wang LJ; Jin C; Chen QJ; Schmidt AM; Shen WF
Chin Med J (Engl); 2010 Mar; 123(5):594-8. PubMed ID: 20367988
[TBL] [Abstract][Full Text] [Related]
20. Rosiglitazone prevents advanced glycation end products-induced renal toxicity likely through suppression of plasminogen activator inhibitor-1.
Yu X; Li C; Li X; Cai L
Toxicol Sci; 2007 Apr; 96(2):346-56. PubMed ID: 17264099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
